製品名:7-bromo-2-(1-methylpyrazol-4-yl)quinoxaline

IUPAC Name:7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline

CAS番号:1083325-87-4
分子式:C12H9BrN4
純度:95%+
カタログ番号:CM327356
分子量:289.14

包装単位 有効在庫 価格(USD) 数量
CM327356-1g in stock ƻƻƅŭ
CM327356-5g in stock Əŭȋş

研究開発用専用.

問い合わせフォーム

   refresh    

製品詳細

CAS番号:1083325-87-4
分子式:C12H9BrN4
融点:-
SMILESコード:CN1N=CC(C2=NC3=CC(Br)=CC=C3N=C2)=C1
密度:
カタログ番号:CM327356
分子量:289.14
沸点:
MDL番号:
保管方法:

Category Infos

Pyrazoles
Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
Pyrazone
Custom pyrazone for customers from all over the world are our main business.
Quinoxalines
Quinoxalines, also known as benzopyrazines, are heterocyclic compounds containing a ring complex consisting of a benzene ring and a pyrazine ring. It has isomerism with other naphthalene compounds such as quinazoline, phthalazine, cinnamine, etc. Fusion N-heterocyclic compounds are widely used as valuable entities for the expansion of important pharmacological agents and are considered to be an advantageous scaffold material. Among the numerous fused N-heterocyclic compounds, cinnoline, quinoxaline and quinazoline are important pharmacological agents. In medicinal chemistry, these N-heterocyclic compounds have a wide range of biological properties and can be used as synthetic intermediates, potential drug candidates and chemical probes.

Column Infos

Erdafitinib
The Janssen Pharmaceutical Companies of Johnson & Johnson announced on September 8, 2023, that it had submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) to seek approval of Erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3) genetic alterations, with disease progression during or following at least one line of therapy containing a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-[L]1) inhibitor.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products